New hope for kids with rare muscle disease: experimental drug trial shows promise
NCT ID NCT05524311
Summary
This study tested whether adding the drug baricitinib to standard steroid treatment works better for children newly diagnosed with juvenile dermatomyositis, a rare and serious autoimmune disease that causes muscle weakness and skin rashes. Sixteen children aged 3-18 participated in this 24-week trial, comparing the new combination to the usual treatment of steroids plus methotrexate. The goal was to see if baricitinib could more effectively control the disease, especially in its severe forms, with an acceptable safety profile.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for JUVENILE DERMATOMYOSITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hopital Necker - Enfants malades : unité d'immuno-hématologie et rhumatologie
Paris, France
-
Hôpital Brabois
Nancy, France
-
Hôpital Femme Mère Enfant
Bron, France
-
Hôpital Jeanne de Flandre
Lille, France
-
Hôpital La Timone
Marseille, France
-
Hôpital Necker - Enfants malades : service de dermatologie
Paris, France
-
Hôpital Pellegrin
Bordeaux, France
-
Hôpital Purpan
Toulouse, France
-
Hôpital Robert Debré
Paris, France
-
Hôpital Trousseau
Paris, France
-
Hôpital Villeneuce
Montpellier, France
-
Hôpital de Hautepierre
Strasbourg, France
-
Hôpital du Kremlin-Bicêtre
Paris, France
Conditions
Explore the condition pages connected to this study.